Afamitresgene autoleucel
PreclinicalCell therapy
RocheAfamitresgene autoleucel is one of 6 therapeutic programs targeting Synovial Sarcoma. It is currently in Preclinical.
1
Indications
0
Total Trials
0
Active Trials
5
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
5 competitors in Synovial Sarcoma
#DrugCompanyPhaseTrials
1DTIC-Dome
BayerApproved
Fludara
SanofiPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Fludara
SanofiPhase 1
TBI-1301
UUnknown Sponsor
Phase 3
Afamitresgene autoleucel
RochePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for Afamitresgene autoleucel. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy
- Highest Phase
- Preclinical
- Company